Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May-Jun;10(Suppl 3):29-40.
doi: 10.6004/jadpro.2019.10.4.12. Epub 2019 May 1.

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Alix Beaupierre  1 , Nicole Kahle  1 , Rachel Lundberg  1 , Amy Patterson  1
Affiliations
Review

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Alix Beaupierre et al. J Adv Pract Oncol. 2019 May-Jun.

Abstract

Two anti-CD19 chimeric antigen receptor (CAR) T-cell therapies are approved for adults with relapsed or refractory large B-cell lymphoma after more than two lines of therapy. Although CAR T-cell therapy has demonstrated significant efficacy for some patients, the treatment process can be long and complex and each phase is associated with unique challenges. Care for patients receiving CAR T-cell therapy also involves many health-care players, including physicians, advanced practitioners, nurse coordinators, nurse educators, apheresis nurses, inpatient and outpatient nurses, cellular therapy technologists, case managers, social workers, and many more. Dedicated educational efforts for patients, caregivers, and clinical providers that make up the multidisciplinary care team are warranted for optimal treatment. Here we present an overview of key elements for education along the treatment journey with CAR T-cell therapy, including considerations for each stage of therapy and specific recommendations for care teams, patients, and caregivers. We also present examples of educational programs that have been implemented at our institution.

PubMed Disclaimer

Conflict of interest statement

This manuscript was sponsored by Kite, a Gilead Company. Ms. Beaupierre, Ms. Kahle, and Ms. Patterson have served on the speakers bureau for Kite, a Gilead Company. Ms. Lundberg has no conflicts of interest to disclose.

References

    1. Abramson J. S., Gordon L. I., Palomba M. L., Lunning M. A., Arnason J. E., Forero-Torres A.,…Siddiqi T. (2018). Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL [Abstract 7505]. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 36(15 suppl). 10.1200/JCO.2018.36.15_suppl.7505 - DOI
    1. Adkins S. (2019). CAR T-cell therapy: Adverse events and management. Journal of the Advanced Practitioner in Oncology, 10(suppl 3), 21–28. 10.6004/jadpro.2018.10.4.11 - DOI - PMC - PubMed
    1. Baxter Healthcare Corporation (2013). Cyclophosphamide (Cytoxan) package insert.
    1. Better M., Chiruvolu V., & Sabatino M. (2018). Overcoming challenges for engineered autologous T cell therapies. Cell & Gene Therapy Insights, 4(4), 173–186. 10.18609/cgti.2018.014 - DOI
    1. Hallek M., Schmitt B., Wilhelm M., Busch R., Kröber A., Fostitsch H.-P.,…Emmerich B. (2001). Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): Results of a phase II study of the German CLL Study Group. British Journal of Haematology, 114(2), 342–348. 10.1046/j.1365-2141.2001.02959.x - DOI - PubMed

LinkOut - more resources